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Abstract We have recently developed a method to produce 
native human proinsulin using a bacterial expression system. A 
proinsulin fusion protein was recovered from inclusion bodies and 
cleaved using cyanogen bromide. The released proinsulin 
polypeptide was 5-sulfonated and purified by anion exchange 
Chromatograph). Following refolding, proinsulin was purified by 
reversed-phase high-performance liquid chromatography. Com-
bined peptide mapping and mass spectrometric analysis indicated 
that the proinsulin contained the correct disulfide bridging 
pattern. This proinsulin will be used to study the specificity of 
the furin/PC family of converting enzymes by using it as a 
substrate in a recently developed assay. 
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have generally been incomplete, presumably to protect propri-
etary interests [9,12-14]. 
We have developed a method which allows us to express 
proinsulin in bacteria by combining the procedures of both 
published and partially described, proprietary methods. In 
short, a fusion protein composed of an N-terminal polyhisti-
dine affinity tag, a methionine residue, and the human proin-
sulin sequence was constructed in a bacterial expression vec-
tor. Following expression, proinsulin was cleaved from the 
polyhistidine tail, purified, and then refolded into its native 
state. The recombinant proinsulin was analyzed by mass spec-
trometry and peptide mapping to verify its identity and the 
formation of the correct disulfide bridging pattern. This re-
combinant proinsulin can be used in future studies for ana-
lyzing the specificity of PCI and PC2. 
1. Introduction 
Many biologically active peptides and proteins are pro-
duced as inactive or less active precursors which must undergo 
enzymatic cleavage or processing to obtain their full potency 
[1-3]. The first hormone shown to be produced via a precur-
sor was proinsulin [4]. Recently, proinsulin has been shown to 
be processed by members of the furin/PC family of propeptide 
converting enzymes (PCEs). PCI cleaves proinsulin at a pair 
of basic amino acids located between the B chain and C-pep-
tide, while PC2 cleaves between the C-peptide and A chain 
[5,6]. 
To examine further the specificity of these PCEs, we need to 
be able to routinely produce milligram quantities of native 
proinsulin for kinetic studies. Bacterial expression systems 
have been used to produce many mammalian proteins and 
peptides [7,8]. The expressed proteins have been used in a 
variety of different 'applications such as antigen production, 
structural studies and biochemical or cell biological assays. 
While bacteria have some disadvantages, including the ab-
sence of intracellular sorting and packaging mechanisms, 
they do have many advantages over mammalian expression 
systems. These advantages include ease of maintaining bacte-
rial cultures, high level expression of recombinant proteins, 
and the simplicity of E. coli genetics. In recent years, a num-
ber of attempts have been made to express both insulin and 
proinsulin in bacteria [9-14]. These attempts have included 
both expression of the B and A chains separately, and the 
expression of intact proinsulin. Many of these attempts failed 
because of N-terminal proteolytic degradation of the recombi-
nant protein within bacterial cells [11]. Other groups have 
successfully produced proinsulin, but their published reports 
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2. Materials and methods 
Human proinsulin was the gift of Eli Lilly and Co. (Indianapolis, 
IN). The human cDNA library was obtained from Clontech (Palo 
Alto, CA), and the bacterial expression system was from Qiagen 
(Chatsworth, CA). Synthetic oligonucleotides were synthesized, and 
automated DNA sequencing was performed in the molecular biology 
core facility of Creighton University. Competent XL2-Blue MRF' 
bacteria were obtained from Stratagene (LaJolla, CA), and restriction 
endonucleases were from New England Biolabs (Beverly, MA). Staph-
ylococcus aureus V8 protease was obtained from Sigma Chemical Co. 
(St. Louis, MO). 
2.1. PCR amplification of human proinsulin 
Oligonucleotide primers were designed with specific restriction sites 
for BamHl and Sail (5' and 3', respectively) which allowed for direc-
tional cloning into the vector pQE-31 (Qiagen). In addition, the prim-
er contained the DNA sequence coding for the amino acid methionine 
immediately 5' of the proinsulin coding sequence. 
A human pancreas cDNA library (Clontech) was used as a tem-
plate, together with the specific primers, in the polymerase chain re-
action (PCR) amplification of the human proinsulin coding sequence. 
The amplified DNA was analyzed by agarose (1.0%) gel electropho-
resis to check for purity and proper size of the amplified product. The 
cDNA was ethanol precipitated and then resuspended in a small vol-
ume of dH20. The cDNA concentration was determined using 
Hoescht dye fluorescence. 
The PCR product and pQE-31 expression vector were cut with the 
appropriate endonucleases, BamHI and San. The vector was dephos-
phorylated by treatment with calf intestinal phosphatase (CIP), and 
both the dephosphorylated vector and cut PCR fragment were etha-
nol precipitated and quantitated as described above. The PCR prod-
uct was then cloned into the pQE-31 expression vector using Ready-
to-go T4 DNA ligase (Pharmacia Biotech). The ligations were per-
formed at 12°C for 15 min in a sonicator waterbath. 
The newly constructed plasmid, hPI/pQE-31, was transformed into 
XL2-Blue MRF' ultracompetent cells (Stratagene). Transformed bac-
teria were grown at 37°C on LB/ampicillin plates, and individual 
colonies were picked and grown overnight at 37°C in 4 ml LB broth 
containing 100 ug/ml ampicillin. The bacteria were collected by cen-
trifugation, and plasmid DNA was purified using the Wizard DNA 
purification system (Promega). A portion of the plasmid DNA was 
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digested with the endonucleases BamHl and Sail, and loaded onto a 
0.8% agarose gel to verify the presence of the proinsulin cDNA insert. 
Integrity of the insert DNA was verified by both automated and 
manual DNA sequencing, and sequence alignment was performed 
using Geneworks (version 2.3) software on a Macintosh computer. 
2.2. Expression screening for proinsulin 
A culture of hPI/pQE-31 containing bacteria was grown in 5 ml LB/ 
ampicillin (100 |ig/ml) overnight and 1 ml of the overnight culture was 
used to inoculate 9 ml of prewarmed LB/ampicillin. The culture was 
grown in a shaking incubator at 37°C until Am reached approx. 0.7-
0.8. Protein expression was induced by the addition of isopropyl-ß-D-
thiogalactopyranoside (IPTG) to a final concentration of 0.5 mM and 
the culture was grown for an additional 3 h. Cells were harvested by 
centrifugation at 5000 Xg for 10 min at 4°C and the bacterial pellet 
was resuspended in 2 ml of ice cold 100 mM Tris-HCl, pH 7.3. 
Cellular membranes were disrupted by probe sonication (two cycles 
of 5 s on, 5 s off) and insoluble proteins were obtained by centrifu-
gation at 15000Xg for 10 min at 4°C. The pellet was resuspended in 
1 ml of 20 mM Tris-HCl, pH 8.2, 7 M urea and shaken at room 
temperature for 30 min. Urea insoluble material was removed by 
centrifugation at 15 000Xg for 10 min at 4°C. Total protein was 
determined by the Bradford method (Bio-Rad) [15]. Protein expres-
sion was analyzed using sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) by loading 10 ug of total protein, 
from the urea soluble fraction, onto a 15% polyacrylamide gel. Pro-
teins were stained with Coomassie blue for 15 min and individual 
proteins were visualized by destaining with 0.5 M NaCl. 
2.3. Small scale protein expression 
A 1 1 culture of hPI/pQE-31 containing bacteria was grown and 
protein expression induced as described above. Cells were harvested 
by centrifugation at 5000Xg for 10 min at 4°C, and the bacterial 
pellets were resuspended in 5 ml/g (wet wt. bacteria) of 100 mM 
Tris-HCl, pH 7.3. Lysozyme was added at a concentration of 1 mg/ 
ml and placed on a rotating shaker at room temperature for 15 min. 
The lysate was subjected to probe sonication for two cycles of 30 s on/ 
30 s off at 4°C. Cellular debris was removed by centrifugation at 
1000Xg for 5 min at 4°C. The supernatant was retained and centri-
fuged again at 27000Xg for 15 min at 10°C to pellet the inclusion 
bodies. The supernatant was discarded and the pellet resuspended in 
1 ml/g (original wt. bacteria) of dH20, aliquoted into 1.5 ml micro-
centrifuge tubes as 1 ml fractions, and then centrifuged at 16000Xg 
for 5 min at 4°C. The pellets were individually washed with 1 ml of 
100 mM Tris-HCl, pH 8.5, 1 M urea, 1.0% Triton X-100, and again 
with 100 mM Tris-HCl, pH 8.5, 2 M urea, 2.0% Triton X-100. The 
pellets were resuspended in 1 ml of dH20 and transferred to a pre-
weighed 30 ml Corex centrifuge tube. The sample was centrifuged at 
15000Xg for 5 min at 4°C, and the pellet was resuspended in 10 ml/g 
(wet wt. pellet) of 70% formic acid. Cyanogen bromide was added to a 
final concentration of 400 mM and the sample was incubated at room 
temperature in the dark for 16 h. The reaction was stopped by trans-
ferring the sample to a round bottom flask and removing the solvent 
by rotary evaporation at 50°C. The residue was resuspended in 20 ml/ 
g (wet wt. pellet) of dH2Ü, shell frozen in a dry ice ethanol bath, and 
then lyophilized. The lyophilized protein was dissolved in 20 ml/g (wet 
wt. pellet) of 500 mM Tris-HCl, pH 8.2, 7 M urea. Oxidative sulfi-
tolysis was performed by adding sodium sulfite and sodium tetrathi-
onate to final concentrations of 100 and 10 mM, respectively, and 
incubating at room temperature for 3 h. This reaction was stopped 
by freezing on dry ice. 
2.4. Purification and refolding of human proinsulin 
The S-sulfonated material was applied to a 2 ml bed of Sephadex 
G-25 equilibrated in 20 mM Tris-HCl, pH 8.2, 7 M urea, and then 
washed with 9 vols. of 7 M urea. The collected fraction was applied to 
a Pharmacia Mono Q HR 5/5 column equilibrated in 20 mM Tris-
HCl, pH 8.2, 7 M urea at a flow rate of 1 ml/min. A linear gradient 
leading to a final concentration of 0.5 M NaCl was used to elute the 
bound material. 2 min (2 ml) fractions were collected during the 
gradient, and protein concentration in each fraction was determined. 
Purity and molecular mass of fractions were estimated by Tricine 
SDS-PAGE [16], where Tricine is used as the trailing ion to allow 
better resolution of peptides in the range of 1-1000 kDa. Appropriate 
fractions were pooled and applied to a 1.6x20 cm column of Sepha-
dex G-25 (superfine) equilibrated in 5 mM ammonium acetate pH 6.8. 
The sample was collected based on UV absorbance and freeze-dried. 
The partially purified S-sulfonated material was resuspended in 50 mM 
glycine/NaOH, pH 10.5 at a final concentration of 2 mg/ml. ß-mer-
captoethanol was added at a ratio of 1.5 mol per mol of cysteine 5-
sulfonate and the sample was stirred at 4°C in an open container for 
16 h. The sample was then analyzed by reversed-phase high-perfor-
mance liquid chromatography (RP-HPLC) using a Vydac C4 column 
(2.2X150 mm) equilibrated in 4% acetonitrile and 0.1% TFA. Ad-
sorbed peptides were eluted with a linear gradient of increasing ace-
tonitrile concentration (0.88% per min up to a maximum of 48%). The 
remaining refolded proinsulin sample was centrifuged for 5 min at 
16000Xg to remove insoluble material, and loaded onto a semi-pre-
parative Vydac C4 column (10x250 mm). The bound material was 
eluted as described above, and the proinsulin was collected and 
lyophilized. 
2.5. Analysis and characterization 
The purified expressed proinsulin was subjected to matrix-assisted 
laser desorption/ionization-time of flight (MALDI-TOF) analysis 
(Protein and Carbohydrate Structure Facility, University of Michi-
gan), using proinsulin from Eli Lilly as both an internal and external 











Fig. 1. Diagram representing the construction of the proinsulin expression plasmid. The PCR amplified Met-proinsulin cDNA containing Bam-
Hl and Saä restriction sites, and the expression vector pQE-31 containing the same restriction sites are shown. The final product of the ligation 
is the expression plasmid containing the Met-proinsulin cDNA. 
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Fig. 2. Diagrammatic representation of the proinsulin fusion protein. The polyhistidine tag is cleaved from proinsulin by CNBr. Note that this 
diagrammatic representation depicts proinsulin with correctly linked disulfide bonds. These bonds have likely not formed when proinsulin is still 
attached to the polyhistidine tag. The sites of normal post-translational processing in islet beta cells are also indicated. 
proteolytic digestion was performed using Staphylococcus aureus pro-
tease V8. 5 ug of both the expressed proinsulin and Eli Lilly's proin-
sulin were lyophilized and resuspended in 50 ul of 250 raM NaP04, 
pH 7.8. Protease V8 was added at a ratio of 1:50 (w/w) in experimen-
tal samples and no enzyme was added to the controls. All samples 
were then incubated overnight at 37°C, the reactions were stopped by 
freezing on dry ice, and samples were stored at —20°C until analyzed. 
The samples were analyzed by RP-HPLC using a Vydac C4 column 
(2.2x 150 mm) equilibrated in 4% acetonitrile and 0.1% TFA. Bound 
material was eluted using a linear gradient of increasing acetonitrile 
concentration (0.88% per min up to a maximum of 48%). 
3. Results 
3.1. Design of the bacterial expression system 
The human proinsulin cDNA sequence was PCR amplified 
from a human pancreas cDNA library using a 5' primer en-
coding the amino acid methionine immediately upstream of 
the proinsulin coding sequence (Fig. 1). A 1% agarose gel was 
run to verify the presence of the proper size PCR product, and 
only a single band was present with an estimated size of ap-
prox. 300 base pairs (data not shown). Following restriction 
enzyme digestion, the insert and vector were ligated together 
at a molar ratio of 5:1. The presence of the insert within the 
plasmid was verified by restriction mapping. Sequence integ-
rity was determined by both automated and manual DNA 
sequencing (data not shown). 
3.2. Protein production 
The expression vector was transformed into an E. coli host 
and expressed intracellularly. The expressed proinsulin fusion 
protein was found to accumulate as insoluble inclusion 
bodies, as determined by SDS-PAGE analysis of both the 
soluble and insoluble cellular lysate fractions (data not 
shown). The insoluble inclusion bodies were washed with 
urea and Triton X-100 and the total wet weight of the ob-
tained inclusion bodies was approx. 200 mg/1 of bacterial cul-
ture. This material was solubilized in 70% formic acid and the 
Fig. 3. Anion exchange chromatography of S-sulfonated proinsulin. This peptide was purified using a Mono Q HR 5/5 column (Pharmacia) on 
a BioLogic Work Station (Bio Rad). Fractions were analyzed and showed that the proinsulin is contained within the major peak. 
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Fig. 4. Analytical RP-HPLC of refolded human proinsulin. The peptide was analyzed using a Vydac narrow bore column (2.2 X 150 mm) on a 
Hewlett Packard 1090 LC. 
proinsulin was separated from the N-terminal polyhistidine 
tag by cyanogen bromide cleavage (Fig. 2). After chemical 
cleavage, the material was resuspended in 7 M urea, subjected 
to oxidative sulfitolysis [17,18], and the S-sulfonated proinsu-
lin was purified by anion exchange chromatography (Fig. 3). 
Approx. 5-8 mg of partially purified, 5-sulfonated proinsulin 
was normally obtained from 1 1 of cultured bacteria. Follow-
ing buffer exchange the proinsulin was simultaneously folded 
and re-oxidized at an approximate protein concentration of 2 
mg/ml. The renatured proinsulin was purified by semi-prepar-
ative RP-HPLC, lyophilized, and its purity was checked by 
both analytical RP-HPLC and Tricine SDS-PAGE. Analytical 
RP-HPLC indicated the presence of a single major component 
at 90% purity (Fig. 4). Final yield of properly refolded proin-
sulin was 1-2 mg per 1 of bacterial culture. 
To confirm the identity of this peptide, proinsulin from Eli 
Fig. 5. SDS-PAGE analysis of expressed and purified proinsulin. 
Approx. 10-12 |Xg of protein was loaded in lanes 1-3 and approx. 
5-8 ng of protein was loaded in lanes 4-6 of a 16.5% Tricine SDS-
polyacrylamide gel. Lanes: 1, post sonicate proteins; 2, combined 
urea/Triton X-100 washes; 3, washed inclusion bodies; 4, cyanogen 
bromide cleaved fusion protein; 5, refolded RP-HPLC purified 
proinsulin; 6, proinsulin from Eli Lilly and Co. Protein bands were 
visualized by staining with Coomassie blue. 
Lilly was subjected to chromatography under identical condi-
tions and it eluted with the same retention time. Samples of 
our expressed proinsulin and Eli Lilly proinsulin were then 
mixed together and subjected to the same chromatography 
procedure. The peptides eluted as a single peak (data not 
shown). Tricine SDS-PAGE was then used as an additional 
method for testing sample purity and checking its molecular 
mass (Fig. 5). The stained band seen in lane 3 represents the 
proinsulin fusion protein with an approximate molecular mass 
of 11 000 Da, while lane 5 shows purified recombinant human 
proinsulin with an estimated molecular mass of 9000 Da. The 
expressed proinsulin appears to be highly purified and co-mi-
grates with Eli Lilly's proinsulin (lane 6). 
3.3. Protein analysis 
MALDI-TOF analysis of the recombinant proinsulin veri-
fied the correct molecular mass of our expressed proinsulin 
using proinsulin provided by Eli Lilly as an external standard 
(see Table 1). Following this, both our refolded proinsulin and 
the Eli Lilly sample were combined and analyzed in a separate 
MALDI-TOF experiment. Results from this experiment veri-
fied that both proinsulin samples have the same molecular 
mass. 
To test further whether the recombinant proinsulin had 
refolded properly, a proteolytic digestion was performed using 
S. aureus protease V8. The proteolytic digest was analyzed by 
RP-HPLC, again using proinsulin provided by Eli Lilly as a 
standard. RP-HPLC analysis indicated that V8 digestion of 
both the recombinant and Lilly proinsulin produced identical 
chromatograms (Fig. 6). The peptides generated from our ex-
pressed proinsulin were collected and MALDI-TOF analysis 
of the individual fractions was consistent with the formation 
of the correct disulfide bonds (see Table 1 and Fig. 7). 
4. Discussion 
For more then a century, researchers have studied the roles 
and actions of insulin. In 1967, Steiner and colleagues discov-
ered a precursor to insulin which they named proinsulin [4]. 
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Time (min) 
Fig. 6. Peptide mapping of proinsulin. RP-HPLC of Eli Lilly proinsulin (A) and refolded expressed proinsulin (B) which have been cleaved 
with Siaphylococcus aureus protease V8. Molecular weight of the fragments was determined by MALDI-TOF. Peak 1, fragment 7; peak 2, 
fragment 3; peak 3, fragment 2, and fragment 1 shortened; peak 4, fragment 6; peak 5, fragment 1 (see Fig. 7). 
Human proinsulin is translated as a single polypeptide chain 
and following removal of the signal sequence, it consists of 86 
amino acids crosslinked by three disulfide bridges. Within the 
secretory pathway, fully bioactive insulin is generated by 
cleavage of proinsulin at two different sites, each of which 
have two adjacent basic amino acid residues [19-21]. This 
results in the separation of the cross-linked A and B chains 
from the C-peptide. 
Recently, PCI and PC2 have been implicated as the two 
members of the furin/PC family involved in the processing 
and activation of proinsulin [5,6,22]. The newly discovered 
furin/PC family of serine proteases, believed responsible for 
propeptide conversion, currently consists of seven members, 
including furin [23,24], PACE4 (paired basic amino acid con-
verting enzyme [25,26], PCI (also called PC3) [27,28], PC2 
[29,30], PC4 [31], PC6 (also called PC5) [32,33], and PC7 
[34]. The sequences of the mammalian PCs are homologous 
to the bacterial subtilisins, but exhibit markedly different sub-
strate specificity. Our laboratory is interested in examining the 
specificity of members of this protease family by using proin-
sulin as a model substrate. 
In 1981, investigators at Eli Lilly and Co. reported that 
insulin and proinsulin can be produced in bacteria using re-
combinant DNA technology [9,10]. Bacterial expression of 
human proinsulin has several advantages over eukaryotic ex-
pression (such as yeast, insect, or mammalian expression sys-
tems). First, bacterial genetics are fairly simple in comparison 
with that of eukaryotic systems. Second, bacterial cultures in 
general will produce greater quantities of desired recombinant 
proteins, and therefore facilitate purification of the desired 
polypeptide. Third, bacteria do not express any known forms 
of yeast kex2 [35] or mammalian convertases, which could 
possibly result in the processing of the majority of the ex-
pressed proinsulin before purification. However, the proce-
dures used by Eli Lilly and Co. have never been fully de-
scribed. In addition, previous attempts by other 
investigators had suggested that bacterial expression of proin-
sulin resulted in very poor yields due to N-terminal degrada-
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Fig. 7. Diagrammatic representation of protease V8 mapping of proinsulin. The fractions in white represent fragments that were not detected 
by combined RP-HPLC/MALDI-TOF. The arrow within fragment one indicates an additional cleavage site which was identified by MALDI-
TOF analysis (fragment 1 shortened). 
tion [11]. We have therefore developed a procedure, based 
upon the work of investigators at Eli Lilly and elsewhere 
[9,13,14] to produce proinsulin. 
We designed a fusion protein expression system consisting 
of an N-terminal polyhistidine tail connected to the human 
proinsulin via a methionine residue. The polyhistidine tail was 
added to help stabilize the expressed peptide and prevent N-
terminal degradation, and could be used for affinity purifica-
tion if needed. The expressed fusion protein was found within 
inclusion bodies, which are believed to be non-crystalline, 
amorphous structures, composed of aggregates of partially 
folded proteins [36]. Recovery of washed inclusion bodies is 
usually performed by low speed centrifugation and repeated 
washing with detergents and denaturants. These washes help 
remove contaminants such as unlysed whole cells, peptidogly-
can cell walls and soluble proteins [37] which may interfere 
with purification. The inclusion bodies were then solubilized 
Table 1 
Matrix-assisted laser desorption/ionization-time of flight (MALDI-
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in 70% formic acid and the polyhistidine tail cleaved from the 
proinsulin using cyanogen bromide. The proinsulin was then 
subjected to oxidative sulfitolysis which results in the forma-
tion of cysteine S-sulfonate derivatives [9]. This derivatization 
protects the sulfhydryl group from reaction with other thiols 
and/or irreversible oxidation, and in addition, pairs of S-sul-
focysteines can be converted to cystine by simple air oxida-
tion. The rate of this reaction can be altered, and mismatched 
disulfides can be broken (to allow proper refolding) by the 
addition of sulfhydryl compounds. An additional advantage 
is that this highly charged version of proinsulin can be parti-
ally purified by anion exchange chromatography. Following 
removal of the urea and buffer salts, the protein is then re-
folded in the presence of low concentrations of ß-mercapto-
ethanol [9]. The refolded proinsulin was then purified by semi-
preparative RP-HPLC and analysed by analytical RP-HPLC 
and Tricine SDS-PAGE. It appears that our expressed form 
of proinsulin is greater than 90% pure. 
Eli Lilly has previously conducted extensive testing on their 
recombinant human proinsulin to assure proper refolding of 
the disulfide bonds [13]. Additional information was obtained 
by testing isoforms of mismatched disulfide bonded human 
insulin, which apparently are separable from native insulin 
using RP-HPLC [14]. We therefore compared our recombi-
nant proinsulin with the proinsulin provided by Eli Lilly. Ini-
tially, we checked that our proinsulin has the same molecular 
mass as the Eli Lilly proinsulin. To assure that proper refold-
ing and disulfide bond formation of our proinsulin had oc-
curred, V8 protease was then used for peptide mapping. 
Under the conditions used, this protease hydrolyzes peptide 
bonds at the carboxyl side of glutamyl and aspartyl residues. 
After V8 digestion of proinsulin, there should be seven frag-
ments created by eight potential cleavage sites (Fig. 7). Com-
bined RP-HPLC and mass spectrometric analysis identified 
five of the seven fragments within a mass error of 0.1 "-". 
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The two smallest fragments (unshaded wedges, Fig. 7) were 
not detected. Fragment one has a theoretical mass of 2973.4 
Da, but due to the presence of an N-terminal glutamine, cyc-
lization occurs with a reduction in mass of 18.0 Da. Johnson 
[14] also reported that V8 is able to cleave between Ser-77 and 
Leu-78 within fragment one (see Fig. 7). This fragment appa-
rently coeluted with fragment two during RP-HPLC, and was 
also identified by mass spectrometry. Based on the results 
from these analyses, we believe that we have obtained authen-
tic human proinsulin in a form suitable for use in our propep-
tide conversion assay. 
Because proinsulin contains three disulfide bonds, and the 
presence of these disulfide bonds can be confirmed by struc-
tural characterization, we feel that the three-dimensional 
structure of proinsulin in vitro will approximate the three-
dimensional structure of proinsulin in vivo. We are, therefore, 
interested in using our expressed proinsulin as a substrate for 
examining the three-dimensional specificity of the propeptide 
converting enzymes PCI and PC2. Using this model system, 
and having the ability to produce milligrams quantities of 
proinsulin, we should now be able to determine the exact 
site of PCE-mediated cleavage based on the results of mass 
spectrometric analysis of the reaction products. In addition, 
because we can produce modified expression plasmids in our 
laboratory, we should be able to alter the structure of the 
proinsulin using the techniques of DNA mutagenesis. This 
will allow us to modify the three-dimensional interactions be-
tween the enzyme and its propeptide substrate. Eventually, we 
hope to be able to predict, or possibly change, the specificity 
of potential processing sites recognized by individual members 
of the furin/PC family of enzymes. 
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